학술논문
Combining the androgen receptor inhibitor darolutamide with PI3K/AKT/mTOR pathway inhibitors has superior efficacy in preclinical models of prostate cancer
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445